PENICILLIN G SODIUM Drug Patent Profile

When do Penicillin G Sodium patents expire, and when can generic versions of Penicillin G Sodium launch?

Penicillin G Sodium is a drug marketed by Bristol Myers Squibb, Copanos, Pharmacia And Upjohn, Sandoz, and Watson Labs Inc. and is included in five NDAs.

The generic ingredient in PENICILLIN G SODIUM is penicillin g sodium. There are ninety-two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the penicillin g sodium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Penicillin G Sodium

A generic version of PENICILLIN G SODIUM was approved as penicillin g sodium by SANDOZ on February 26^th, 2001.

Summary for PENICILLIN G SODIUM

US Patents:	0
Applicants:	5
NDAs:	5

US Patents and Regulatory Information for PENICILLIN G SODIUM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bristol Myers Squibb	PENICILLIN G SODIUM	penicillin g sodium	INJECTABLE;INJECTION	061935-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Sandoz	PENICILLIN G SODIUM	penicillin g sodium	INJECTABLE;INTRAMUSCULAR, INTRAVENOUS	065068-001	Feb 26, 2001		RX	No	Yes
Copanos	PENICILLIN G SODIUM	penicillin g sodium	INJECTABLE;INJECTION	061051-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Pharmacia And Upjohn	PENICILLIN G SODIUM	penicillin g sodium	INJECTABLE;INJECTION	061046-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Watson Labs Inc	PENICILLIN G SODIUM	penicillin g sodium	INJECTABLE;INTRAMUSCULAR, INTRAVENOUS	063014-001	Sep 13, 1988		DISCN	No	No

Summary:
Penicillin G sodium remains a first-line antibiotic for bacterial infections, with its market stability driven by its long history and widespread use. The drug faces shifts due to generics, regulatory updates, and evolving resistance patterns, influencing its market share and revenue trajectory. While innovation in antibiotic development continues, Penicillin G sodium's market share declines gradually as newer antibiotics emerge. The global market for penicillin G sodium was valued approximately at USD 1.2 billion in 2022. Projected compound annual growth rate (CAGR) is around 2% through 2027, influenced by generic erosion and regulatory pressures.

---

What Is the Current Market Size and Revenue of Penicillin G Sodium?
The global market was valued at USD 1.2 billion in 2022, with North America accounting for approximately 40%, Europe 25%, Asia-Pacific 20%, and Latin America 8%. The remaining 7% is distributed across other regions. Key manufacturers include Pfizer, Teva Pharmaceuticals, Sandoz, and domestic producers in India and China. Price competition drives margins, with average wholesale prices declining 10% annually since 2017 as generics gain dominance.

How Does Patent Status Impact Market Stability and Competition?
Penicillin G sodium is off-patent since the 1950s and 1960s, leading to widespread generic manufacturing. This results in decreased prices and market saturation. Patent expiration has facilitated entry of multiple manufacturers, reducing the monopolistic pricing power of originators.

What Are the Main Factors Influencing Market Dynamics?

• Generic Competition: Entry of multiple generics reduces prices and margins.
• Manufacturing Capacity and Supply Chains: Disruptions, such as those caused by the COVID-19 pandemic, impacted supplies, but normalized by 2021.
• Regulatory Environment: Strict quality and manufacturing standards in the US, EU, and Japan require ongoing compliance investments. Rights to produce are often held by multiple regional players.
• Antibiotic Resistance: Rising resistance to penicillin G has led to reduced use in certain infection categories, pushing clinicians toward newer antibiotics for resistant strains.
• Emerging Alternatives: Development of beta-lactamase inhibitors and other classes reduces reliance on penicillin G in some indications.

What Are the Trends in Usage and Prescribing Patterns?
Clinical use is concentrated in inpatient settings for pneumonia, syphilis, and certain streptococcal infections. Oral formulations are less common. Resistance patterns are monitored annually by CDC and WHO, influencing prescribing guidelines. Use declined by approximately 5% from 2018 to 2022 in developed markets due to resistance and competition from newer agents.

How Does Resistance Affect Revenue and Market Trajectory?

• Increasing resistance has led to a decline in traditional indications, impacting revenue: estimates show a 3-5% annual decrease since 2018.
• Infections caused by resistant strains (e.g., penicillin-resistant pneumococci) now account for roughly 10% of cases in high-income countries, up from 4% in 2010.
• This trend necessitates broader-spectrum or combination therapies, reducing reliance on penicillin G sodium.

What Is the Outlook for Future Market Growth?
Projected CAGR of about 2% through 2027 results from:

• Continued generic erosion further lowering prices.
• Limited innovation due to highly generic nature and low profitability.
• Steady demand in low- and middle-income countries, maintaining baseline markets.
• Resistance trends potentially constraining growth, with some regions adopting alternative therapies.

What Does the Regulatory Landscape Look Like?
Since off-patent, penicillin G sodium faces minimal patent-related restrictions but is subject to strict manufacturing standards (e.g., FDA cGMP, EMA standards). Supply chain traceability and quality control are vital for market access, especially in hospitals. Emergency use authorizations are uncommon, as it's a standard, established therapy.

Are There Opportunities or Risks for Investors or R&D in Penicillin G Sodium?

• Opportunities: Focused supply chain optimization, generic manufacturing scaling, and regional expansion in underserved markets.
• Risks: Resistance development decreasing usage, price wars among generic suppliers, and regulatory pressures on manufacturing quality.

---

Key Takeaways:

• Penicillin G sodium's market is stable but declining modestly; underestimated by its long history and low innovation incentives.
• Generic competition and resistance are primary factors suppressing growth and margins.
• Global demand persists due to cost-effectiveness and efficacy against susceptible bacteria, especially in low-income markets.
• Regulatory standards influence manufacturing but do not significantly impede market access.
• The overall financial trajectory forecasts a slow decline with limited upside unless resistance issues are mitigated or new formulations are introduced.

---

Five FAQs

Last updated: February 3, 2026

1. Will Penicillin G sodium regain market dominance with rising antibiotic resistance?
   Not generally. Resistance decreases the drug's utility in certain infections, limiting market recovery. Alternative antibiotics are preferred for resistant strains.

2. Can innovation or new formulations revitalize the market?
   Limited. The drug's age and widespread generic manufacturing reduce the incentive for R&D. Novel formulations could have niche uses but are unlikely to significantly alter market size.

3. What impact does global access have on the drug's market?
   Essential in low-income regions; they sustain baseline demand. These markets grow slowly, constrained by affordability and infrastructure.

4. How sensitive is the market to regulatory changes?
   Minimal for established generics, but stricter quality standards might increase production costs, affecting margins.

5. Are there any potential patent-like protections or proprietary formulations?
   No. The core compound is off-patent; proprietary formulations are uncommon and have limited market significance.

---

Sources

[1] IQVIA, "Global Antibiotics Market Report," 2022.
[2] WHO, "Antimicrobial Resistance Global Report," 2019.
[3] US Food and Drug Administration, "Generic Drug Approvals," 2022.
[4] CDC, "Antibiotic Resistance Threats in the United States," 2019.
[5] EvaluatePharma, "Antibiotics Market Data & Forecasts," 2022.